Live biotherapeutic products are not conventional biologics with a microbial backstory. The microorganism itself forms part of the active product.
That distinction changes the entire manufacturing programme.
A recombinant protein process can remove the production organism and purify the molecule it created. A live biotherapeutic must preserve the organism’s identity, viability, phenotype, potency, purity, stability, and therapeutic function through banking, fermentation, recovery, formulation, filling, storage, and administration.
That makes the choice of a live biotherapeutics cdmo far more consequential than selecting available fermentation capacity.
The strongest partner must understand microbiology, anaerobic process engineering, genomic safety, cell banking, contamination control, formulation, analytical development, GMP systems, clinical supply, and commercial scale-up as one connected route. It must protect the delicate intimacy between organism, environment, and biological function without losing sight of cost, reproducibility, or regulatory expectations.
The following thirteen requirements define what sponsors should expect from a serious live biotherapeutics cdmo.
1. Define the biological product before designing the process
The programme must first establish what the medicine actually is.
A live biotherapeutic may contain:
- one naturally derived strain;
- one engineered microorganism;
- a spore-forming organism;
- vegetative cells;
- a defined microbial consortium;
- an anaerobe, microaerophile, facultative anaerobe, or aerobe.
The team must also define the mechanism, dose, route, patient population, product presentation, target shelf life, and clinical stage.
The product’s ontology comes first: which biological entity constitutes the medicine, which physiological state must remain intact, and what function defines potency?
A spore product, engineered bacterium, stool-derived isolate, and multi-strain consortium do not require the same banking, fermentation, analytical, containment, or formulation strategy.
A capable live biotherapeutics cdmo starts with the product definition rather than forcing every organism into a standard microbial platform.
2. Establish strain identity, provenance, and genomic safety
Species-level identification is not enough.
Two strains from the same species may differ substantially in metabolism, therapeutic activity, antimicrobial resistance, virulence potential, manufacturing behaviour, and environmental persistence.
A complete strain-characterisation package may include:
- source and isolation history;
- whole-genome sequencing;
- strain-level identification;
- plasmid status;
- passage history;
- mobile genetic elements;
- virulence-associated genes;
- antimicrobial-resistance genes;
- horizontal gene-transfer risk;
- chain of custody.
The genomic sequence should connect clearly to the production bank and remain traceable throughout development.
For engineered strains, the programme must also confirm insert identity, genetic stability, containment features, auxotrophy where applicable, kill-switch behaviour, and the absence of unintended genomic changes.
The strain arrives with a biological history. Manufacturing must preserve and document it.
3. Build master and working cell banks that preserve phenotype
A cell bank is not merely frozen starting material. It is the biological origin of every future batch.
The banking strategy may include a research cell bank, master cell bank, and working cell bank, each supported by controlled documentation and defined passage limits.
Testing should address:
- identity;
- purity;
- viability;
- genomic stability;
- phenotype;
- therapeutic function;
- recovery after thaw;
- productivity;
- storage conditions;
- long-term stability.
For strict anaerobes, oxygen control must continue during culture, filling, freezing, storage, thawing, and recovery. A bank that survives storage but loses its relevant phenotype has not preserved the product.
The organism should not behave like a Lizard repeatedly carried between incompatible climates. Recovery conditions must resemble the biological environment selected during development.
A leading live biotherapeutics cdmo protects both genotype and phenotype from the first controlled bank onward.
4. Control anaerobic and microaerophilic conditions throughout manufacturing
Anaerobic fermentation alone is not enough.
Oxygen-sensitive organisms may lose viability during media preparation, inoculation, sampling, harvesting, washing, concentration, formulation, filling, or storage. A brief exposure can reduce recovery before the batch shows any visible sign of failure.
The process may require control of:
- redox potential;
- gas composition;
- oxygen ingress;
- deoxygenated media;
- reducing agents;
- closed transfers;
- anaerobic chambers;
- vessel headspace;
- sampling systems;
- filling atmosphere;
- final-container oxygen.
Bulk dissolved-oxygen measurements may also conceal local gradients near spargers, impellers, vessel walls, and transfer points. Oxygen-transfer and redox mapping therefore matter for unusually sensitive strains.
Some organisms tolerate only a narrow, almost intimate chemical atmosphere. Once oxygen enters that space, the cells may withdraw from the very function the programme depends upon.
The best live biotherapeutics cdmo treats anaerobic control as an unbroken manufacturing chain.
5. Develop fermentation around viable function, not biomass
The largest fermentation is not necessarily the best fermentation.
Maximum optical density, wet-cell weight, or total biomass may occur after the culture has already begun losing viability, potency, metabolic function, surface characteristics, or post-processing stability.
Development should evaluate:
- media composition;
- carbon and nitrogen sources;
- pH;
- temperature;
- gas composition;
- agitation;
- redox;
- growth phase;
- metabolite accumulation;
- viable count;
- functional phenotype;
- harvest timing.
A culture can continue growing whilst producing inhibitory metabolites, entering stress, changing surface proteins, or losing resistance to freezing and drying.
The development team should identify the point at which the process contains the greatest quantity of recoverable, functional organisms rather than extending the batch simply because biomass continues to rise.
The objective is not maximum growth.
It is maximum useful biology.
6. Scale up without losing phenotype
Scale-up changes the physical world surrounding the organism.
A process that performs well at two litres may behave differently at 200 or 2,000 litres because mixing, heat removal, gas transfer, redox distribution, pressure, shear, and substrate gradients all change with vessel geometry.
A robust scale-up strategy examines:
- mixing time;
- oxygen and redox microgradients;
- carbon-dioxide accumulation;
- heat transfer;
- gas flow;
- agitation;
- shear;
- nutrient distribution;
- residence time;
- sampling delays;
- harvest logistics.
The goal is not to reproduce identical numerical settings. It is to reproduce the biological conditions that created the desired phenotype.
Scale-down models can help simulate large-vessel gradients and reveal whether the organism maintains viability, metabolic function, surface properties, sporulation behaviour, and potency under commercial conditions.
A serious live biotherapeutics cdmo scales the phenotype, not merely the volume.
7. Control spore formation, germination, and physiological state
For Bacillus, Clostridia, and other spore-forming organisms, physiological state can become a critical quality attribute.
The intended product may contain:
- purified spores;
- vegetative cells;
- a defined mixture;
- spores designed to germinate after administration.
Manufacturing may need to control:
- sporulation timing;
- sporulation efficiency;
- spore purity;
- residual vegetative cells;
- heat resistance;
- germination behaviour;
- dose uniformity;
- storage stability.
A process that produces high biomass but inconsistent sporulation may create variable release performance. Conversely, excessive processing intended to enrich spores may damage germination or alter potency.
The programme must define whether the therapeutic function depends on the dormant state, the transition into vegetative growth, or activity after germination.
The state of the organism is part of the product.
8. Preserve viability during harvesting and downstream recovery
Downstream processing for a live therapeutic differs fundamentally from recombinant-protein purification.
The process does not aim to reduce the product to one purified molecule. It aims to remove unwanted material while protecting living cells and their function.
Operations may include:
- centrifugation;
- filtration;
- washing;
- concentration;
- buffer exchange;
- cryoprotectant addition;
- lyoprotectant addition;
- controlled cooling;
- closed transfer.
Risks include:
- shear damage;
- osmotic shock;
- oxygen exposure;
- warm hold times;
- excessive washing;
- cell loss;
- phenotype changes;
- membrane damage.
Each recovery step should track viable yield, not only total biomass.
The process must recover the organism without manufacturing it into biological silence.
A well-designed live biotherapeutics cdmo programme connects fermentation and downstream development early so that harvest conditions support recovery rather than delivering stressed cells into an unforgiving process.
9. Integrate formulation, drying, packaging, and fill-finish
Formulation cannot sit apart from manufacturing.
A living product must survive storage, shipment, dosing, and delivery to the intended site. The formulation therefore becomes part of the organism’s controlled environment.
Possible formats include:
- frozen liquid;
- lyophilised powder;
- spray-dried material where suitable;
- capsule;
- sachet;
- enteric-coated presentation;
- anaerobically filled container.
Development may evaluate cryoprotectants, lyoprotectants, excipients, residual moisture, water activity, oxygen transmission, headspace composition, packaging, shipping temperature, and reconstitution.
Formulation is less a single recipe than a layered Painting of excipients, moisture, packaging, oxygen, temperature, and time.
It becomes the organism’s final embrace: too severe and the cells suffer; too permissive and heat, moisture, or oxygen slowly undoes the product.
A complete live biotherapeutics cdmo should link formulation with drying, filling, packaging, and shelf-life strategy rather than handing the organism across disconnected technical groups.
10. Build analytics around identity, viability, purity, and potency
A live count does not fully define a live therapeutic.
The analytical strategy should answer four questions.
Identity methods may include strain-specific PCR, sequencing, genomic assays, and phenotypic confirmation.
Viability methods may include CFU, flow cytometry, live/dead assays, viability PCR, recovery studies, and evaluation of viable-but-non-culturable states.
Purity testing may address environmental organisms, adventitious agents, cross-contamination, residual process materials, and strain-ratio control for consortia.
Potency assays should reflect the intended mechanism, which may involve:
- metabolite production;
- pathogen inhibition;
- immune modulation;
- epithelial interaction;
- barrier support;
- target-specific biochemical activity;
- consortium function.
CFU shows how many organisms form colonies under defined conditions. Potency shows whether the product still performs the biological function for which it was designed.
A leading live biotherapeutics cdmo also develops precision viable-cell dosing so that the final container delivers a controlled functional dose rather than an approximate biomass target.
11. Control contamination, cross-contamination, and bacteriophages
Microbial manufacturing intentionally grows organisms at high density. That makes contamination control both more difficult and more important.
The facility must distinguish the desired production organism from:
- environmental contaminants;
- another manufacturing strain;
- bacteriophages;
- raw-material contaminants;
- processing organisms from previous campaigns.
Controls may include:
- facility segregation;
- campaign planning;
- environmental monitoring;
- closed processing;
- validated cleaning;
- raw-material controls;
- strain-specific detection;
- personnel flows;
- phage surveillance;
- rapid campaign-response plans.
Bacteriophages deserve special attention. One phage event can slow growth, alter process behaviour, destroy a fermentation, or create subtle inconsistency before operators understand the cause.
For multi-strain manufacturing, cross-contamination may involve a valid organism in the wrong product.
Good contamination control protects the product’s biological identity, not merely the cleanliness of the room.
12. Apply GMP, containment, and regulatory systems designed for living organisms
Live microbial products require quality systems that account for growth, adaptation, genetic stability, environmental persistence, and contamination risk.
Phase-appropriate GMP controls may include:
- qualified raw materials;
- controlled cell banks;
- batch records;
- environmental monitoring;
- specifications;
- analytical qualification;
- stability protocols;
- deviations;
- change control;
- comparability;
- clinical-supply planning.
Engineered organisms may require additional containment and biosafety controls covering environmental release, shedding, persistence, genetic transfer, reversion, mutation, auxotrophy, and kill-switch performance.
The regulatory package may need to connect the strain, genome, bank, process, potency assay, formulation, stability, and clinical material clearly enough to support IND or CTA review.
A good live biotherapeutics cdmo does not impose full commercial validation on an early programme, but it builds foundations that will not collapse when the project advances.
13. Maintain one scientific thread from isolate to patient
A live therapeutic remains one continuous biological product even when it passes through several departments, sites, and development phases.
The programme must connect:
- isolate;
- genome;
- cell bank;
- phenotype;
- fermentation;
- scale-up;
- harvest;
- recovery;
- formulation;
- fill-finish;
- analytics;
- stability;
- clinical supply;
- post-administration tracking.
An LBP programme can resemble a biological Kaleidoscope: one change in oxygen, growth phase, strain ratio, drying condition, or formulation can rearrange the complete functional pattern.
The greatest failures often occur at handoffs:
- discovery to banking;
- banking to process development;
- fermentation to recovery;
- formulation to fill-finish;
- development site to GMP facility;
- manufacturing to clinical analytics.
Elise supports live microbial programmes by connecting strain biology, anaerobic handling, fermentation, recovery, formulation, analytical development, and phase-appropriate manufacturing within one development path.
The organism remains continuous even when departments change.
Its manufacturing history must remain continuous as well.
What sponsors should expect from an LBP manufacturing partner
A leading manufacturing partner should be able to answer the following questions clearly:
| Area | Central question |
|---|---|
| Product definition | What organism and function constitute the medicine? |
| Strain identity | Can the strain be distinguished, traced, and genomically assessed? |
| Cell banking | Does the bank preserve viability, identity, and phenotype? |
| Anaerobic control | Can oxygen remain controlled from inoculum through filling? |
| Fermentation | Does the process maximise recoverable function? |
| Scale-up | Can the phenotype survive larger vessels? |
| Recovery | Can cells be concentrated without damaging viability? |
| Formulation | Will the product survive storage, delivery, and administration? |
| Analytics | Are identity, viability, purity, dose, and potency demonstrated? |
| Contamination | Are unwanted organisms and phages controlled? |
| GMP | Do quality systems reflect the risks of a living product? |
| Clinical supply | Can the process support consistent, documented batches? |
| Technology transfer | Can the biological knowledge move with the process? |
Conclusion
A leading live biotherapeutics cdmo must control far more than fermentation.
It must preserve strain identity, genomic safety, phenotype, viability, purity, potency, dose, and shelf life from the original isolate through the final clinical product. It must understand anaerobic biology, scale-up physics, downstream recovery, spore state, contamination, bacteriophages, formulation, fill-finish, analytical strategy, containment, and regulatory documentation.
The best development model treats these elements as one manufacturing system.
Elise Biopharma helps sponsors build live microbial programs around the actual biology of the organism. That means creating controlled cell banks, developing scalable fermentation, protecting cells during recovery, designing stable final formats, establishing mechanism-relevant analytics, and preparing the process for GMP manufacturing and clinical supply.
A live therapeutic is not simply produced.
It is carried through a process designed to keep its biological identity and function intact.
Learn more about our –> Enzyme CDMO Services
Email our team at info@elisebiopharma.com